Valuation: Q-linea AB

Capitalization 512M 56.69M 48.25M 44.81M 42.01M 78.23M 5.19B 82.94M 203M 2.45B 213M 208M 8.98B P/E ratio 2025 *
-2.93x
P/E ratio 2026 * -4.58x
Enterprise value 512M 56.69M 48.25M 44.81M 42.01M 78.23M 5.19B 82.94M 203M 2.45B 213M 208M 8.98B EV / Sales 2025 *
24.5x
EV / Sales 2026 * 4.78x
Free-Float
2.25%
Yield 2025 *
-
Yield 2026 * -
More valuation ratios * Estimated data
Dynamic Chart
1 day+1.46%
1 week+2.37%
Current month+11.01%
1 month+23.81%
3 months+10.04%
6 months-41.47%
Current year+11.01%
More quotes
1 week 26
Extreme 26
30.45
1 month 23
Extreme 22.995
38.42
Current year 24.51
Extreme 24.51
38.42
1 year 20.78
Extreme 20.785
574
3 years 20.78
Extreme 20.785
14,500
5 years 20.78
Extreme 20.785
170,000
10 years 20.78
Extreme 20.785
187,500
More quotes
Manager TitleAgeSince
Chief Executive Officer 48 2025-10-18
Director of Finance/CFO 62 2017-12-31
Director of Finance/CFO 64 2023-04-30
Director TitleAgeSince
Director/Board Member 55 2024-02-29
Chairman 64 2017-12-31
Director/Board Member 57 2020-05-25
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
+1.46%+2.37%-90.71%-99.79% 56.69M
-1.59%-1.08%+3.41%-38.81% 18.88B
+0.87%-12.44%+134.84%+155.14% 2.76B
-7.64%-14.37%-35.87%-68.75% 2.08B
-3.51%-4.76%-6.84%-14.49% 1.19B
+0.88%0.00%+23.53%-39.77% 915M
+1.37%-3.48%+8.45%-40.36% 873M
+0.12%-2.73%-27.51%-42.53% 672M
-0.73%+3.05%-0.21%-33.85% 602M
Average -0.92%-2.15%+1.01%-24.80% 3.11B
Weighted average by Cap. -1.62%-1.33%+12.81%-21.09%
See all sector performances

Financials

2025 *2026 *
Net sales 20.9M 2.32M 1.97M 1.83M 1.72M 3.2M 212M 3.39M 8.28M 100M 8.68M 8.51M 367M 107M 11.86M 10.09M 9.37M 8.79M 16.36M 1.09B 17.35M 42.4M 513M 44.46M 43.55M 1.88B
Net income -170M -18.82M -16.01M -14.87M -13.94M -25.96M -1.72B -27.53M -67.29M -814M -70.56M -69.11M -2.98B -101M -11.17M -9.51M -8.83M -8.28M -15.41M -1.02B -16.34M -39.94M -483M -41.88M -41.03M -1.77B
Net Debt - -
More financial data * Estimated data
Logo Q-linea AB
Q linea AB is a Sweden-based medical technology company. The Company develops and manufactures in-vitro diagnostic (IVD) solutions for infectious diseases. The Company's core product candidate is ASTar, a fully-automated instrument for Antibiotic Susceptibility Testing (AST). It measures bacteria's antimicrobial susceptibility using the disposables developed by the Company. It is able to provide a susceptibility profile within three to six hours directly from a positive blood culture, which enables early administration of antibiotics specifically targeting the disease-causing pathogen. Its main application is the identification of sepsis in hospital patients and the product is aimed primarily at hospital laboratories.
Employees
83
More about the company
Date Price Change Volume
26-01-23 27.68 kr +2.54% 2,316
26-01-22 27.00 kr -1.68% 105,854
26-01-21 27.46 kr +1.70% 17,699
26-01-20 27.00 kr +1.87% 17,639
26-01-19 26.50 kr -2.00% 36,234

Delayed Quote Nasdaq Stockholm, January 23, 2026 at 09:05 am

More quotes

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. QLINEA Stock